How is sarcomatoid renal cell carcinoma (SRCC) treated?

Updated: Mar 11, 2019
  • Author: Ronald J Cohen, MB, BCh, PhD, FRCPA, FFPATH; Chief Editor: Liang Cheng, MD  more...
  • Print


Treatment of metastatic SRCC with interferon and/or interleukin-2 immunotherapy gives a partial response in 33% of patients but extends median survival only from 7 months to 19 months. [3]

Similarly, combination chemotherapy regimens such as doxorubicin plus gemcitabine are reported to give complete or partial responses in 40% of cases, but with a median response duration of only 5 months. [58] A study investigating treatment of metastatic SRCC with the antiangiogenic agents sunitinib, sorafenib, or bevacizumab showed a partial response in only 19% of patients, with a mean response duration of 9 months. [59] Interestingly, the partial responses were limited to those patients who had SRCC arising from clear cell renal cell carcinoma (CCRCC), with less than 20% of the tumor volume comprised of sarcomatoid elements.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!